))
7.4 million Americans could gain Medicare or Medicaid coverage for anti-obesity drugs under Biden proposal
Manage episode 453571222 series 3609475
Conteúdo fornecido por Esther C Kane CAPS, C.D.S., Esther C Kane CAPS, and C.D.S.. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Esther C Kane CAPS, C.D.S., Esther C Kane CAPS, and C.D.S. ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Summary of article found on WREX.com:
The Biden administration proposed expanding Medicare and Medicaid coverage for costly anti-obesity drugs, potentially benefiting millions of seniors and low-income individuals. This could significantly reduce out-of-pocket expenses, but the proposal lacks details and faces uncertainty under the incoming Trump administration, with differing opinions from key appointees.
Currently, limited access due to high drug costs restricts widespread use, and the financial implications for Medicare are substantial, with estimates reaching billions of dollars annually. While some private insurers are covering these medications, state Medicaid programs show varied levels of coverage, highlighting the cost concerns and potential challenges in broader implementation.
34 episódios
Compartilhar
